Published in Biochemistry on May 15, 2001
Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity. J Biol Chem (2009) 1.30
Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem (2008) 1.15
Synthesis and biological applications of collagen-model triple-helical peptides. Org Biomol Chem (2010) 1.05
Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry (2007) 1.05
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem (2008) 1.03
Exosite interactions impact matrix metalloproteinase collagen specificities. J Biol Chem (2011) 1.02
Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc (2007) 1.00
Defining requirements for collagenase cleavage in collagen type III using a bacterial collagen system. J Biol Chem (2012) 0.98
Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities. Biochem J (2004) 0.98
MMP-12 catalytic domain recognizes triple helical peptide models of collagen V with exosites and high activity. J Biol Chem (2008) 0.97
Targeted drug delivery utilizing protein-like molecular architecture. J Am Chem Soc (2007) 0.96
Development of a solid-phase assay for analysis of matrix metalloproteinase activity. J Biomol Tech (2004) 0.94
Chemical biology for understanding matrix metalloproteinase function. Chembiochem (2012) 0.92
Characterization of an exosite binding inhibitor of matrix metalloproteinase 13. Protein Sci (2007) 0.90
Using fluorogenic peptide substrates to assay matrix metalloproteinases. Methods Mol Biol (2001) 0.88
Activatable Optical Probes for the Detection of Enzymes. Curr Org Synth (2011) 0.84
Designed triple-helical peptides as tools for collagen biochemistry and matrix engineering. Philos Trans R Soc Lond B Biol Sci (2007) 0.81
Comparison of metalloproteinase protein and activity profiling. Anal Biochem (2010) 0.79
Enzymatic turnover of macromolecules generates long-lasting protein-water-coupled motions beyond reaction steady state. Proc Natl Acad Sci U S A (2014) 0.79
The role of collagen charge clusters in the modulation of matrix metalloproteinase activity. J Biol Chem (2013) 0.79
Cartilage stem/progenitor cells are activated in osteoarthritis via interleukin-1β/nerve growth factor signaling. Arthritis Res Ther (2015) 0.78
Identification of collagen binding domain residues that govern catalytic activities of matrix metalloproteinase-2 (MMP-2). Matrix Biol (2012) 0.78
Extracellular matrix turnover in coronary artery ectasia patients. Heart Vessels (2015) 0.78
Stabilization of collagen-model, triple-helical peptides for in vitro and in vivo applications. Methods Mol Biol (2013) 0.78
Development of a Förster resonance energy transfer assay for monitoring bacterial collagenase triple-helical peptidase activity. Anal Biochem (2014) 0.77
Analysis of flavonoid-based pharmacophores that inhibit aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases through the use of topologically constrained peptide substrates. Chem Biol Drug Des (2009) 0.76
The synthesis and application of Fmoc-Lys(5-Fam) building blocks. Biopolymers (2013) 0.75
Early infiltration of p40IL12(+)CCR7(+)CD11b(+) cells is critical for fibrosis development. Immun Inflamm Dis (2016) 0.75
Matrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analogues. Chembiochem (2015) 0.75
Fluorogenic Peptide Substrate for Quantification of Bacterial Enzyme Activities. Sci Rep (2017) 0.75
Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc Natl Acad Sci U S A (2003) 5.50
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet (1992) 5.14
Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci U S A (1992) 4.13
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 3.22
Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem (1999) 3.06
A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int J Pept Protein Res (1990) 2.98
A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem (1986) 2.65
ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature (1991) 2.60
TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem (2001) 2.58
Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem (1992) 2.43
Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem (1999) 2.33
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Coordinative binding of divalent cations with ligands related to bacterial spores. Equilibrium studies. Biophys J (1971) 2.10
Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers (1996) 2.07
Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry (1990) 2.06
Cloning and heterologous expression of the epothilone gene cluster. Science (2000) 2.06
The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res (1998) 1.94
Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (1998) 1.90
Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology (1998) 1.75
Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest (1992) 1.74
Degradation of chromosomal DNA during apoptosis. Cell Death Differ (2003) 1.73
Solid phase peptide synthesis of 15N-gramicidins A, B, and C and high performance liquid chromatographic purification. Int J Pept Protein Res (1989) 1.71
Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis (1989) 1.71
Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem (1996) 1.69
Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res (1992) 1.55
The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J Biol Chem (1988) 1.54
Human plasma kallikrein. A rapid purification method with high yield. Biochem J (1981) 1.53
Tumor cell invasion, matrix metalloproteinases, and the dogma. Lab Invest (1994) 1.52
Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther (1992) 1.51
Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). J Biol Chem (1994) 1.49
Detection of 12 germ-line mutations in the adenomatous polyposis coli gene by polymerase chain reaction. Gastroenterology (1993) 1.49
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res (1992) 1.47
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem (1997) 1.45
Structural properties of matrix metalloproteinases. Cell Mol Life Sci (1999) 1.43
Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest (1989) 1.42
Purification of an endogenous activator of procollagenase from rabbit synovial fibroblast culture medium. J Biol Chem (1983) 1.42
Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem (1995) 1.42
Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett (1988) 1.39
Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol (1999) 1.38
Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases. J Biol Chem (2000) 1.35
Sequence specificities of human fibroblast and neutrophil collagenases. J Biol Chem (1991) 1.34
Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res (1998) 1.33
Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem (2000) 1.32
Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem (1994) 1.32
The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J (1988) 1.30
An improved assay for proteases and polysaccharidases employing a cartilage proteoglycan substrate entrapped in polyacrylamide particles. Anal Biochem (1980) 1.29
Continuously recording fluorescent assays optimized for five human matrix metalloproteinases. Anal Biochem (1991) 1.28
Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J (1992) 1.27
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem (1988) 1.25
Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase. Arch Biochem Biophys (1988) 1.24
Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb (1994) 1.23
Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int (1997) 1.23
A precursor form of latent collagenase produced in a cell-free system with mRNA from rabbit synovial cells. J Biol Chem (1981) 1.22
A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J Biol Chem (1999) 1.22
Interaction of gentamicin and spermine with bilayer membranes containing negatively charged phospholipids. Biochemistry (1985) 1.21
Recognition and catabolism of synthetic heterotrimeric collagen peptides by matrix metalloproteinases. Chem Biol (2000) 1.21
Biosynthesis and secretion of procollagenase by rabbit synovial fibroblasts. Inhibition of procollagenase secretion by monensin and evidence for glycosylation of procollagenase. Biochem J (1983) 1.21
Sequence specificity of human skin fibroblast collagenase. Evidence for the role of collagen structure in determining the collagenase cleavage site. J Biol Chem (1987) 1.20
Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem (1995) 1.20
Purification of the neutral proteoglycan-degrading metalloproteinase from human articular cartilage tissue and its identification as stromelysin matrix metalloproteinase-3. Biochem J (1989) 1.20
Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res (1999) 1.20
Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthritis Rheum (1998) 1.19
Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet (1998) 1.19
Insights into MMP-TIMP interactions. Ann N Y Acad Sci (1999) 1.18
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. Dev Genet (1997) 1.18
The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP. Biochemistry (1997) 1.18
Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem (1998) 1.17
Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli. FEBS Lett (1996) 1.16
Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res (1994) 1.16
Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer (1995) 1.14
Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J (1995) 1.14
Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis (1991) 1.13
The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem (1997) 1.13
Identification of plasma kallikrein as an activator of latent collagenase in rheumatoid synovial fluid. Biochim Biophys Acta (1982) 1.13
Defining the domains of type I collagen involved in heparin- binding and endothelial tube formation. Proc Natl Acad Sci U S A (1998) 1.12
Micropatterning gradients and controlling surface densities of photoactivatable biomolecules on self-assembled monolayers of oligo(ethylene glycol) alkanethiolates. Chem Biol (1997) 1.11
Opioid-induced cardioprotection against myocardial infarction and arrhythmias: mitochondrial versus sarcolemmal ATP-sensitive potassium channels. J Pharmacol Exp Ther (2000) 1.11
Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol (2002) 1.08
Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases. J Biol Chem (1997) 1.08
Chemokines induce eosinophil degranulation through CCR-3. J Allergy Clin Immunol (2000) 1.08
Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol (1994) 1.08
CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell (1996) 1.07
Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum Mol Genet (1994) 1.07
Cellular recognition of synthetic peptide amphiphiles in self-assembled monolayer films. Biomaterials (1999) 1.07
Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett (1999) 1.07
Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann N Y Acad Sci (1999) 1.06
Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res (1995) 1.05
Multiple forms of the APC gene transcripts and their tissue-specific expression. Hum Mol Genet (1993) 1.05
Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol (2001) 1.05
The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol (1992) 1.05
Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol (1987) 1.04
Ligand accessibility as means to control cell response to bioactive bilayer membranes. J Biomed Mater Res (2000) 1.04
Increased level of translatable collagenase messenger ribonucleic acid in rabbit synovial fibroblasts treated with phorbol myristate acetate or crystals of monosodium urate monohydrate. Biochemistry (1982) 1.04